The SLC17A (solute carrier family 17) family comprises a group of membrane transport proteins that play key roles in the transport of a variety of substrates, including organic anions, phosphates, and neurotransmitters. Members of this family are primarily known as phosphate transporters (SLC17A1-4) and vesicular glutamate transporters (VGLUTs, SLC17A5-7). The phosphate transporters are involved in the renal reabsorption of phosphate, a critical process for maintaining phosphate homeostasis, bone mineralization, and overall metabolic function. The VGLUTs are crucial in the central nervous system, where they transport glutamate into synaptic vesicles, facilitating excitatory neurotransmission. The signaling and function of SLC17A transporters are essential in various physiological processes, from bone health to nerve communication, and their dysfunction is implicated in several diseases, including neurological disorders and phosphate metabolism abnormalities.
Targeting SLC17A signaling for disruption or inhibition with small molecules enables a more detailed understanding of the diverse roles these transporters play in physiological and pathological processes. By inhibiting specific SLC17A transporters, researchers can delineate their individual contributions to phosphate homeostasis and neurotransmitter regulation. Such targeted approaches are crucial in elucidating the mechanisms of diseases related to phosphate imbalance or glutamate signaling disorders. Additionally, the use of small molecule inhibitors can shed light on the potential targets within the SLC17A family for conditions like osteoporosis or neurodegenerative diseases.
VOIR ÉGALEMENT...
Items 1 to 10 of 23 total
Afficher:
Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
---|---|---|---|---|---|---|
6-Nitro-7-sulfamoylbenzo[f]quinoxaline-2,3-Dione | 118876-58-7 | sc-478080 | 5 mg | $70.00 | 1 | |
Le NBQX est un antagoniste des récepteurs AMPA, qui peut indirectement affecter la signalisation et la libération du glutamate. | ||||||
D(−)-2-Amino-5-phosphonovaleric acid (D-AP5) | 79055-68-8 | sc-200434 | 5 mg | $95.00 | 2 | |
En tant qu'antagoniste des récepteurs NMDA, l'AP5 peut influencer indirectement la signalisation et la libération du glutamate. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $204.00 | 2 | |
Le CNQX est un antagoniste puissant des récepteurs AMPA, qui affecte indirectement la signalisation et la libération du glutamate. | ||||||
Kynurenic acid | 492-27-3 | sc-202683 sc-202683A sc-202683B | 250 mg 1 g 5 g | $25.00 $56.00 $135.00 | 6 | |
Il s'agit d'un antagoniste à large spectre des récepteurs des acides aminés excitateurs, qui réduit la signalisation du glutamate. | ||||||
Riluzole | 1744-22-5 | sc-201081 sc-201081A sc-201081B sc-201081C | 20 mg 100 mg 1 g 25 g | $20.00 $189.00 $209.00 $311.00 | 1 | |
Le riluzole inhibe la libération de glutamate, influençant indirectement la fonction de SLC17A7. | ||||||
Memantine hydrochloride | 41100-52-1 | sc-203628 | 50 mg | $68.00 | 4 | |
Il s'agit d'un antagoniste des récepteurs NMDA, qui affecte indirectement la signalisation du glutamate. | ||||||
Ethosuximide | 77-67-8 | sc-211431 | 1 g | $300.00 | ||
Ce composé réduit l'activité des canaux calciques de type T, ce qui peut indirectement influencer la libération de glutamate. | ||||||
Lamotrigine | 84057-84-1 | sc-201079 sc-201079A | 10 mg 50 mg | $118.00 $476.00 | 1 | |
La lamotrigine inhibe les canaux sodiques sensibles au voltage, ce qui entraîne une diminution de la libération de glutamate. | ||||||
Topiramate | 97240-79-4 | sc-204350 sc-204350A | 10 mg 50 mg | $105.00 $362.00 | ||
Il module les courants évoqués par le GABA, influençant indirectement la libération de glutamate. | ||||||
Felbamate | 25451-15-4 | sc-203579 sc-203579A | 10 mg 50 mg | $101.00 $373.00 | ||
Le felbamate agit comme un antagoniste des récepteurs NMDA, affectant indirectement la signalisation et la libération du glutamate. |